Compare AIV & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | PHAR |
|---|---|---|
| Founded | 1975 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1994 | N/A |
| Metric | AIV | PHAR |
|---|---|---|
| Price | $5.94 | $17.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 2.2M | 26.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 47.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.72 | 0.00 |
| Revenue | $210,889,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $6.96 | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ $3.85 | $3,006.53 |
| Revenue Growth | ★ 39.67 | 26.78 |
| 52 Week Low | $5.24 | $7.50 |
| 52 Week High | $9.29 | $18.30 |
| Indicator | AIV | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 51.55 |
| Support Level | $5.53 | $16.55 |
| Resistance Level | $5.81 | $18.30 |
| Average True Range (ATR) | 0.11 | 0.80 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 84.16 | 41.02 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.